Wealth Enhancement Advisory Services LLC Acquires 19,641 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 140.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,594 shares of the company's stock after purchasing an additional 19,641 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Apellis Pharmaceuticals were worth $1,072,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after purchasing an additional 758 shares in the last quarter. Signaturefd LLC increased its position in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after acquiring an additional 918 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth about $83,000. US Bancorp DE boosted its position in Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Apellis Pharmaceuticals by 1,819.2% during the 4th quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after purchasing an additional 3,784 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS traded down $0.01 during mid-day trading on Thursday, reaching $19.26. The company had a trading volume of 1,302,533 shares, compared to its average volume of 2,328,857. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -9.49 and a beta of 0.68. The business's 50-day simple moving average is $18.32 and its 200 day simple moving average is $25.44. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $43.76. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. During the same period in the prior year, the business earned ($0.54) earnings per share. Apellis Pharmaceuticals's quarterly revenue was down 3.2% compared to the same quarter last year. On average, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on APLS shares. Scotiabank decreased their target price on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Citigroup dropped their target price on shares of Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a report on Thursday, May 22nd. Royal Bank of Canada cut their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Cantor Fitzgerald assumed coverage on Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $44.00 price target on the stock. Finally, Needham & Company LLC cut their price objective on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.05.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).